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association between average costs and rate of SU use was not significant. Other 
therapy classes were associated with increased costs with the exception of 
premixed insulin, meglitinides and amylinomimetics (no significant association) 
and biguanides and alpha glucosidase inhibitors (negative association). 
CONCLUSIONS: Use of SU could potentially increase complications in type 2 
diabetes.  
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OBJECTIVES: Many patients on antidiabetics do not reach the ADA-
recommended A1c level (<7%). This cross-sectional epidemiologic study 
evaluated A1c levels and diabetes-related complications among commercially 
insured US patients receiving antidiabetics. METHODS: Patients aged ≥18 years, 
diagnosed with T2DM, with ≥1 oral antidiabetic or insulin fill and continuous 
pharmacy and medical health plan enrollment for 2008, 2009, 2010, or 2011 were 
selected from the HealthCore Integrated Research DatabaseSM, an integrated 
claims dataset representing a large national health insurer. Characteristics and 
outcomes were assessed descriptively. RESULTS: We identified 265,411 patients 
for 2008, 266,104 for 2009, 264,220 for 2010 and 229,079 for 2011. Electronic A1c 
lab results were available for 22.2% of patients. In 2008 48.2% of patients had an 
A1c <7%; the percentage of patients achieving this target decreased through 2011 
with only 44.5% achieving an A1c <7%. The percentage of patients with an A1c 
≥9% increased from 15.3% in 2008 to 17.7% in 2011. Mean A1c was 7.47, 7.55,  
7.50, and 7.62 for the years 2008, 2009, 2010, and 2011, respectively. An analysis 
of the 2011 population revealed that patients with an A1c <7% were less likely to 
have neuropathy (7.1% vs.10.5%), retinopathy (8.0% vs. 12.3%), or 
amputations/ulcerations (1.6% vs. 2.7%), compared to patients with an A1c ≥7% 
(P<0.001 for each). The 2011 average A1c for patients with versus without 
neuropathy was 7.97 versus 7.59; for retinopathy, 7.89 versus 7.59; and for 
amputation/ulceration, 8.13 versus 7.61. CONCLUSIONS: These results suggest 
that diabetes management in the US over the past four years has worsened in 
this sample of commercially insured patients, with potentially adverse cost 
consequences. Diabetes-related complications were more common in patients 
with worse diabetes control. As more than half of patients had A1c levels above 
the ADA recommendation, the study highlights the unmet need for improved 
glycemic control.  
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OBJECTIVES: Diabetes FORWARD (DF) is a practice-based research network 
(PBRN) focused on Type-2 Diabetes (T2DM) health technology assessment (HTA) 
and health services research (HSR) in North America, based in primary care 
practices with electronic medical records (EMR) and enriched with 
supplementary patient- and provider-reported information. Recruitment is 
currently 9% of goal, with interest in early evaluations of how the DF source 
population might relate to other T2DM populations. METHODS: Eligible patients 
are adults with T2DM receiving pharmacotherapy, and other criteria previously 
reported. We examined the T2DM cohort of the DF-EMR, the DF population 
enrolled between March and September 2012 (DF), and members with 
continuous enrollment through 2011 in a large commercial health plan (LHP). We 
reviewed preliminary descriptive information to inform future analyses of 
patient subgroups and outcomes among populations in these data sources. 
RESULTS: DF-EMR source population (n=187,991) and DF patients (n=935) varied 
from LHP (n=719,041) in ways to be expected from sources created for different 
purposes. DF-EMR and DF had slightly greater proportions of males versus LHP, 
respectively (48.1 and 43.6 vs. 54.2%), and a US geographic distribution skewed 
toward the South (62.6 and 68.4 vs 42.0%). Insurance types reflected the nature of 
the data sources: Commercial, 51.1 and 47.4 versus 87.2%; Medicare, 41.9 and 39.8 
versus 6.1%; and Medicaid, 1.5 and 7.7 versus 0.3%. The DF population had 
slightly greater prevalence of insulin (18.6 vs. 17.3%) and oral antidiabetic drug 
(OAD) use versus LHP, reflecting the DF pharmacotherapy criterion: No OAD, 7.4 
versus 45.7%; 1 OAD, 43.1 versus 27.6%; 2 OAD, 37.4 versus 18.2%; 3 or more OAD, 
12.1 versus 8.2%. CONCLUSIONS: HTA and HSR require complementary data 
sources to translate findings into improved outcomes across patients and 
settings. This descriptive assessment begins to investigate the potential 
applicability of findings across populations from such important complementary 
data sources.  
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OBJECTIVES: Type-2 diabetes is the most common metabolic disease in Italy and 
in developed countries. It is the sixth leading chronic disease by diffusion with a 
crude prevalence of 4.9%. It is estimated that about 3,000,000 Italians suffer from 
this pathology. In the last decade, the new class of incretin-based therapies 
entered the arena, but their place in therapy remains difficult to determine 
because of limited long-term clinical data on both effectiveness and safety,  
and the high cost of therapy. Both injectable glucagon-like peptide1(GLP-1) 
receptor agonists (incretin-mimetics) and orally-administered inhibitors of 
dypeptidylpeptidase-4(DPP-4) produce a significant improvement in glycemic 
control especially when combined with metformin, similar to other second-line 
therapies, but additional advantages with respect to weight gain and overall 
hypoglycemia. In 2008 AIFA established a Monitoring Registry through which 
collecting and monitoring the safety and the efficacy profiles of new antidiabetic 
drugs. METHODS: Data collected from the Monitoring Registry from 2008 to 2011 
were analyzed. An estimation of population enrolled, NHS-expenditures and 
median cost for patients were calculated for the antidiabetic drugs which 
entered in the Registry. RESULTS: AIFA Antidiabetic Monitoring Registry enrolled 
135,954 patients for the period of observation. 79,211 patients (58%) were treated 
with DPP-4 (saxagliptin, vildagliptin and sitagliptin associated or not with 
metformin) and 56,743 patients (42%) with GLP-1 analogous (liraglutide and 
exenatide) with an economic NHS burden on Registry respectively equal to 
€34,675,414 (55%) and €28,649,091 (45%). The daily mean cost per patient related 
to the drugs included in the Registry was around €3. CONCLUSIONS: The safety 
and efficacy profiles of drugs monitored in the Italian real-world clinical practice 
are similar to those recorded during phase 2-3 registration clinical trials. Data 
collected through Registry allows performing a cost-effectiveness analysis and a 
cost-impact for NHS comparing both the monitored drugs among them and the 
other therapeutic treatments  
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OBJECTIVES: To describe the demographic and clinical characteristics, 
antidiabetic medication use and glycemic control among diabetic nursing home 
(NH) residents with moderate to severe chronic kidney disease (CKD). METHODS: 
Long term care administrative data with linked clinical and functional 
assessments, demographic information, laboratory results and pharmacy claims 
were analyzed. Residents with diabetes who remained in NHs for at least 90 
consecutive days in 2008-2011 and had at least one estimated glomerular 
filtration rate (eGFR) test and one glycated hemoglobin (HbA1c) test within 1 year 
of the continuous stay were selected. Residents with moderate to severe CKD 
were identified if they had an eGFR less than 60 mL/min/1.73m2. Resident 
demographic characteristics, comorbidities, and functional status were 
summarized. Use of antidiabetic medications was assessed for the first 90-day 
period of the continuous NH stay. Proportion with glycemic control was also 
assessed. RESULTS: Of the 1005 long-stay diabetic NH residents, 338 (33.6%) had 
moderate to severe CKD. CKD residents were on average 74.4 ± 11.1 years old and 
majority of them were females (59.8%). Common comorbidities included 
hypertension (93.2%), depression (77.8%) and anemia (56.2%). 72.8% of the 
residents were receiving ≥9 medications. Less than half (42.0%) of the residents 
received oral antidiabetic drugs (OAD) or glucagon-like peptide-1 agonist, and a 
higher proportion received insulin (61.8%). The most commonly used OAD was 
sulfonylurea (22.2%), followed by metformin (13.3%). The average HbA1c was 
7.0% ± 1.5; 59.8% had HbA1c<7%, 19.2% had HbA1c >7% and ≤8%, 11.8% had 
HbA1c >8% and ≤9%, and 9.2% had HbA1c>9%. CONCLUSIONS: The prevalence of 
moderate or severe CKD is high in long-stay diabetic nursing home residents. 
Less than two thirds of the residents with CKD had glycemic control. Medication 
therapy management to achieve better glycemic control should be considered for 
NH residents particularly among those with CKD.  
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OBJECTIVES: To assess the association between non-concordant use of oral anti-
diabetic drug treatment (OAD) according to National Kidney Foundation (NKF) 
guidelines and prescribing information (PI) and severe hypoglycemic events and 
hospital re-admission in hospitalized type 2 diabetes mellitus (T2DM) patients 
with stage 3-5 chronic kidney disease (CKD). METHODS: This study analyzed 
electronic health records from integrated health systems across the U.S. Adult 
T2DM patients with stage 3-5 CKD, who were hospitalized between 2008 and 
2011, were identified from medical diagnoses, dialysis procedures, or laboratory 
findings. OADs prescribed on the discharge date were evaluated and considered 
not concordant if any were not prescribed according to NKF guidelines or PI. 
Separate Cox-proportional hazards models were used to evaluate the 
associations of NKF and PI non-concordance with re-admission and severe 
hypoglycemic events controlling for patient demographic and clinical 
characteristics, respectively. RESULTS: A total of 1712 patients (mean age: 68.4; 
50.5% female; 69.6% stage-3 CKD) met the criteria for NKF guidelines evaluation 
and 1552 patients (mean age: 68.2; 50.5% female; 70.6% stage-3 CKD) for PI 
evaluation. The non-concordance rate was 36.4% for NKF and 71.8% for PI. After 
adjusting for patient characteristics, patients who were not concordant to PI 
were more likely to have severe hypoglycemic events (HR: 1.62, 95 % CI: 1.11-2.37) 
and re-admission (HR: 1.36, 95 % CI: 1.16-1.61) after being discharged. On the 
other hand, we did not find any statistically significant associations between 
non-NKF-concordance with severe hypoglycemic events (HR: 1.29, 95% CI: 0.98-
